Ligand Pharmaceuticals (LGND) Intangibles (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Intangibles of $217.3 million for Q1 2026, down 3.59% sequentially from $225.4 million in Q4 2025, and down 15.89% YoY from $258.4 million in Q1 2025.
Ligand Pharmaceuticals (LGND) Intangibles (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Intangibles for 17 years, with the latest figure at $217.3 million in Q1 2026.
- Quarterly Intangibles fell 15.89% year-over-year to $217.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $217.3 million (down 15.89% YoY) and the FY2025 annual result came in at $225.4 million, down 15.45% from the prior year.
- Intangibles declined to $217.3 million in Q1 2026 per LGND's latest filing, from $225.4 million in the prior quarter.
- Over five years, Intangibles peaked at $539.7 million in Q1 2022 and troughed at $217.3 million in Q1 2026.
- A 5-year average of $323.7 million and a median of $291.4 million in 2024 frame the typical range for Intangibles.
- The sharpest annual moves came in 2022 and 2023: Intangibles retreated 7.55% in 2022, then plunged 39.1% in 2023.
- Over 5 years, Intangibles stood at $342.5 million in 2022, then retreated by 12.51% to $299.6 million in 2023, then dropped by 11.0% to $266.6 million in 2024, then decreased by 15.45% to $225.4 million in 2025, then slipped by 3.59% to $217.3 million in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $217.3 million, $225.4 million, and $233.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 209.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 209.24 Mn |
| Mar 31, 2026 | 217.34 Mn |
| Dec 31, 2025 | 225.44 Mn |
| Sep 30, 2025 | 233.54 Mn |
| Jun 30, 2025 | 250.13 Mn |
| Mar 31, 2025 | 258.39 Mn |
| Dec 31, 2024 | 266.65 Mn |
| Sep 30, 2024 | 274.91 Mn |
| Jun 30, 2024 | 283.16 Mn |
| Mar 31, 2024 | 291.42 Mn |
| Dec 31, 2023 | 299.61 Mn |
| Sep 30, 2023 | 314.84 Mn |
| Jun 30, 2023 | 325.38 Mn |
| Mar 31, 2023 | 333.92 Mn |
| Dec 31, 2022 | 342.46 Mn |
| Sep 30, 2022 | 517.03 Mn |
| Jun 30, 2022 | 528.36 Mn |
| Mar 31, 2022 | 539.71 Mn |
| Dec 31, 2021 | 376.69 Mn |
| Sep 30, 2021 | 562.37 Mn |